• Citer

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

par Stopeck, Alison;Tonkin, Katia;Shore, Neal;Sieber, Paul;Kueppers, Frank;Karsh, Lawrence;Yardley, Denise;Wang, Huei;Maniar, Tapan;Arellano, Jorge;Braun, Ada;Fizazi, Karim;Body, Jean-Jacques ;Brown, Janet;Carducci, Michael;Diel, Ingo Jakob;Fujiwara, Yasuhiro;Martin, Miguel;Paterson, Alexander H. G.
Référence Supportive care in cancer, 24, 1, page (447-455)
Publication Publié, 2016-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Auteur:	Stopeck, Alison; Tonkin, Katia; Shore, Neal; Sieber, Paul; Kueppers, Frank; Karsh, Lawrence; Yardley, Denise; Wang, Huei; Maniar, Tapan; Arellano, Jorge; Braun, Ada; Fizazi, Karim; Body, Jean-Jacques; Brown, Janet; Carducci, Michael; Diel, Ingo Jakob; Fujiwara, Yasuhiro; Martin, Miguel; Paterson, Alexander H. G.
Informations sur la publication:	Supportive care in cancer, 24, 1, page (447-455)
Statut de publication:	Publié, 2016-01
Sujet CREF:	Cancérologie
Mots-clés:	Bone metastases
	Breast cancer
	Denosumab
	Osteonecrosis of the jaw
	Prostate cancer
	Zoledronic acid
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0941-4355
	info:doi/10.1007/s00520-015-2904-5
	info:scp/84949085967